Dr. Heidi Overton, President Trump's pick to lead the FDA, refused to declare healthcare a "human right" during a tense Senate confirmation hearing, and backed up the administration's record on drug prices with hard numbers that left Sen. Bernie Sanders scrambling to change the subject.
Sanders, the Vermont independent who ranks as the top Democrat on the Senate Health, Education, Labor, and Pensions Committee, spent his questioning time Thursday pressing Overton for a simple yes-or-no endorsement of government-guaranteed healthcare for every American. Overton, a physician who completed her residency at Johns Hopkins in Baltimore and later joined the America First Policy Institute, declined to play along.
Instead, she told the committee she understands the importance of access to care and believes in getting patients the "best care possible." She said she looks forward to carrying out the policies and responsibilities "vested from Congress" to the FDA, a careful answer that kept her squarely inside the lane of the job she was nominated to fill.
The exchange followed a familiar Sanders template. He opened with a broad ideological question designed to box in a nominee:
"Do you happen to believe that healthcare is a human right that should be available to every man, woman and child in our country?"
Overton sidestepped. She said access to healthcare is important, but she did not adopt Sanders' framing. The senator grew visibly frustrated, according to Fox News, and pressed harder. He pointed to Canada as proof that a single-payer system works.
"I live 50 miles away from the Canadian border. Somehow, everybody in that country can go to a doctor."
That line drew no concession from Overton. She pivoted to the Trump administration's actual record on prescription drug costs, citing Consumer Price Index data showing that drug prices fell 3 percent, the first decline in 60 years. She added that 89 percent of branded drugs are now covered by agreements designed to lower prices for American consumers.
Sanders, who has built a career on rallying the progressive left around Medicare-for-all and similar proposals, tried to undercut the numbers. He argued the price decline had more to do with legislation Congress passed years earlier than with Trump administration policy.
"Yeah, which may have something to do with the legislation that we passed several years ago."
He did not name the law. And he did not directly dispute the 3 percent CPI figure Overton cited.
Overton attributed the drop in prescription drug costs to the administration's most-favored-nation policies, an approach that pegs what the U.S. pays for certain drugs to the lower prices negotiated by other developed countries. She framed the result plainly:
"The most-favored nation policies have dropped prices and, right now, CPI says that for the first time in 60 years, prescription drug prices have gone down by 3%."
Sanders had entered the exchange trying to get Overton on the record supporting universal healthcare. He left it arguing over who deserved credit for a drug-price decline he could not deny. He told the committee he was running out of time and moved on.
The moment captured a pattern. Sanders uses confirmation hearings the way he uses campaign rallies, as stages for ideological declarations. He wanted Overton to say the federal government should guarantee healthcare to every person in the country. That is not the FDA commissioner's job. Overton, to her credit, kept her answers within the boundaries of the position she was nominated to hold.
Sanders has argued that the United States is the only major country that does not guarantee healthcare to its citizens and that "thousands" of Americans die because they cannot access or afford care. Those claims are central to his long-running push for a single-payer system, a proposal that has never secured enough votes in Congress despite decades of advocacy from Sanders and allies like Rep. Alexandria Ocasio-Cortez.
The broader Medicare-for-all debate is playing out ahead of November's midterm elections, and Sanders has been busy on multiple fronts. He has pressed major tech companies on artificial intelligence policy and waded into intra-party fights that have fractured the Democratic coalition.
If confirmed, Overton would succeed Dr. Marty Makary, who resigned as FDA commissioner earlier this year. Makary's departure followed a disagreement with the Trump administration over flavored vapes, though the details of that dispute were not disclosed at the hearing.
Overton's background is clinical, not political. She trained at one of the country's top medical institutions before joining the America First Policy Institute, a policy organization aligned with the Trump agenda. That combination, medical credentials plus policy-shop experience, positions her as a nominee who can speak the language of both the exam room and the regulatory apparatus.
Sanders, meanwhile, has been clashing publicly with fellow senators in his own caucus, calling out moderates he views as insufficiently committed to progressive principles. His combative approach at the Overton hearing fits that pattern, less interested in the nominee's qualifications for a specific regulatory post, more interested in extracting a political confession.
No vote on Overton's confirmation was announced at the hearing, and the committee's timeline for advancing her nomination remains unclear. Sanders did not indicate whether he would oppose her, though his line of questioning left little doubt about his posture.
The Vermont senator's track record on endorsements and alliances has itself become a source of friction on the left. He has declined to back certain progressive candidates while aggressively championing others, drawing criticism from activists who expected lockstep solidarity.
What stood out Thursday was not Sanders' performance, his script has not changed in years. What stood out was Overton's discipline. She did not take the bait. She did not wander into a policy debate that has nothing to do with the FDA's statutory mandate. She answered with data, cited the CPI, and let Sanders run out his own clock.
Sanders wanted a headline about a Trump nominee refusing to call healthcare a right. What he got was a physician calmly reciting a 3 percent drug-price decline and an 89-percent coverage rate on branded medications, numbers that pointed back to the administration Sanders was trying to indict.
When a senator has to argue over who deserves credit for good news instead of proving the news is bad, the nominee has already won the exchange.
